Regarding RCC, an interesting study by Schoenfeld et al. investigated how LAG3 expression levels are, on average, lower at metastatic sites than those at primary RCC sites, and how this difference was more enhanced in patients with high-risk clinical features, such as those presenting with a larger primary tumor; with grade 4, IMDC poor-risk disease; or with brain metastases [47]. Here, LAG3 is linked to renal cell carcinoma.